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Given that little is known about the prevalence of, and factors associated with, liver fibrosis in
the general population, we aimed to investigate this in a large, well-characterized cohort by
means of transient elastography (TE). This study was part of the Rotterdam Study, a
population-based study among individuals45 years. All participants underwent abdominal
ultrasound and TE. Liver stiffness measurement (LSM) 8.0 kilopascals (kPa) was used as a
cutoff suggesting clinically relevant fibrosis. Of 3,041 participants (age, 66.06 7.6 years)
with reliable LSM, 169 (5.6%) participants had LSM 8.0 kPa. Age (odds ratio [OR]: 2.40;
95% confidence interval [CI]: 1.72-3.36; P< 0.001), alanine aminotransferase (ALT; OR,
1.24; 95% CI: 1.12-1.38; P< 0.001), smoking (OR, 1.77; 95% CI: 1.16-2.70; P5 0.008),
spleen size (OR, 1.23; 95% CI: 1.09-1.40; P5 0.001), hepatitis B surface antigen, or anti–
hepatitis C virus positivity (OR, 5.38; 95% CI: 1.60-18.0; P5 0.006), and combined pres-
ence of diabetes mellitus (DM) and steatosis (OR, 5.20; 95% CI: 3.01-8.98; P< 0.001 for
combined presence) were associated with LSM 8.0 kPa in multivariable analyses. The
adjusted predicted probability of LSM 8.0 kPa increased per age decade, with probabilities
ranging from 1.4% (0.9-3.6) in participants ages 50-60 years to 9.9% (6.8-14.5) in partici-
pants >80 years. Participants with both DM and steatosis had the highest probabilities of
LSM8.0 kPa (overall probability: 17.2% [12.5-23.4]; this probability did not increase with
age [P5 0.8]). Conclusion: In this large population-based study of older adults, LSM 8.0
kPa, suggestive of clinically relevant fibrosis, was present in 5.6% and was strongly associated
with steatosis and DM. In the context of an aging population and an increased prevalence of
DM and obesity, this study illustrates that liver fibrosis may become a more prominent public
health issue in the near future. (HEPATOLOGY 2016;63:138-147)
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A
dvanced liver fibrosis and cirrhosis affects hundreds
of millions of people and comprises a major cause
of morbidity and mortality, with a world-wide
mortality rate owing to liver cirrhosis (LC) and primary
liver cancer of over 1.5 million per year.1,2 In the United
States, chronic liver disease (CLD) and cirrhosis are the
eleventh leading cause of mortality.3 In the past few deca-
des, nonalcoholic fatty liver disease (NAFLD) has become
one of the major causes of liver disease.4 In previous
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European population-based cohort studies, the reported
prevalence of steatosis, assessed by abdominal ultrasound
(US), ranged from 25% to 35%.5-8 In patients with dia-
betes mellitus (DM), the prevalence of NAFLD was
shown to be as high as 40%-70%.9,10 Considering popu-
lation aging and the current epidemic in obesity and type
II DM in developed countries, the burden of CLDs—in
particular, nonalcoholic steatohepatitis (NASH)—is pro-
jected to increase substantially in the next decades.11-13
To date, limited studies have been performed focusing
on the prevalence of, and risk factors for, liver fibrosis in
the general population, owing to the fact that data are
mainly derived from autopsy studies or biopsy studies in
selected populations. In theory, one way to investigate
the prevalence of liver fibrosis and cirrhosis in the gen-
eral population would be to perform a liver biopsy in a
large population of healthy volunteers. However, an
important disadvantage of liver biopsies is the invasive
nature of the procedure, and healthy volunteers are
rarely representative of the general population at risk. In
recent years, noninvasive techniques have been devel-
oped to circumvent the need for liver biopsy. One of
these techniques is transient elastography (TE), which is
strongly associated with histological stages of liver fibro-
sis.14-19 Previous studies examining factors associated
with elevated liver stiffness measurements (LSMs) in
community-based populations were performed in vol-
unteers attending a free medical checkup and in a Chi-
nese population-based cohort study.20,21 Until now,
these factors have not been studied in a large random
sample of a general Caucasian population. Therefore,
the aim of our study was to investigate the distribution
of, and factors associated with, clinically relevant liver
fibrosis, as measured by TE, in a large population-based
cohort of Caucasians.
Subjects and Methods
Study Population. The Rotterdam Study is a large,
prospective, population-based cohort study conducted
among adults age 45 years and above living in
Ommoord, a district of Rotterdam, The Netherlands.
The rationale and study design have been described previ-
ously.22 The medical ethics committee at the Erasmus
University of Rotterdam approved the study, and written
informed consent was obtained from all participants.
All consecutive participants (age range: 51-98 years)
that visited the research center between January 2011
and September 2013 were included in the current study.
Each participant completed an extensive interview and
clinical examination that included abdominal ultraso-
nography (USG), TE, a fasting blood collection, and an
anthropometric assessment.
Interview. The interview preceded the clinical
examination and was designed to obtain data concern-
ing demographics, medical history, comorbid condi-
tions, current and past smoking behavior, current
alcohol consumption (drinks/week), and drug use.
Detailed information on dispensed drug prescriptions
was obtained from automated pharmacies, where nearly
all participants are registered.
Biochemistry. Fasting blood samples were collected
on the morning of US examination and LSM. Blood
lipids, platelet count, glucose, and alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), gamma-
glutamyltransferase (GGT), alkaline phosphatase (ALP),
and total bilirubin were measured using automatic enzy-
matic procedures (Roche Diagnostics GmbH, Mann-
heim, Germany). Insulin, hepatitis B surface antigen
(HBsAg), and anti-hepatitis C virus (anti-HCV) were
measured by an automatic immunoassay (Roche Diag-
nostics GmbH). According to local cut-off criteria, the
upper limit of normal (ULN) of ALTwas defined as 40
U/L for men and 30 U/L for women.
Abdominal USG. Abdominal USG was performed
by a certified and experienced technician on a Hitachi
HI VISION 900 (Hitachi Medical Corporation, Tokyo,
Japan). Images were stored digitally and reevaluated by
a single hepatologist with more than 10 years of experi-
ence in USG (J.S.). Diagnosis of steatosis was deter-
mined by the US technician according to the protocol
by Hamaguchi et al.23 Severity of fatty liver was
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classified as no fatty liver (score 0-1), mild fatty liver
(score 2-3), or moderate-to-severe fatty liver (score 4-
6). NAFLD was defined as steatosis in the absence of
any of the following possible secondary causes of stea-
tosis: (1) excessive alcohol consumption (>14 drinks/
week); (2) positive HBsAg or anti-HCV tests; and (3)
use of pharmacological agents associated with steatosis
(i.e., amiodarone, corticosteroids, methotrexate, and
tamoxifen). In addition, spleen size, presence of collat-
erals, and Doppler examination of hepatic veins,
hepatic artery, and portal vein were evaluated during
US examination. Splenomegaly was defined as a spleen
size >12.0 cm.
TE. LSM (FibroScan; Echosens, Paris, France)
was performed by a single operator, who carried out
more than 1,000 examinations before the start of the
study. LSM was performed on the right lobe of the
liver, through the intercostal spaces, with the partici-
pant lying flat on his or her back with the right arm
laying in maximal abduction. Either M- or XL-probe
was applied, according to instructions by the manufac-
turer. Participants with intracardiac devices and
participants with physical disabilities, making TE
impossible, were excluded from the study. Because of
necessary maintenance of probes (for calibration), TE
was not performed on 4 days during the study period.
Failure was recorded when no LSM was obtained after
at least 10 shots. Reliability of LSM was categorized
according to the criteria by Boursier et al.24 LSM was
considered poorly reliable if interquartile range (IQR)/
median LSM >0.30 with median LSM 7.1 kilopas-
cals (kPa). These poorly reliable LSMs were excluded
from our analyses. LSM 8.0 kPa and >13.0 kPa
were taken as cutoffs suggesting clinically relevant liver
fibrosis and cirrhosis, respectively. These cut-off levels
were deliberately chosen because they are known to
yield high positive predictive values (PPVs) for pres-
ence of clinically relevant fibrosis and cirrhosis in pre-
vious studies.16,21,25
Covariables. Anthropometric measurements were
performed by well-trained research assistants. Body mass
index (BMI) was calculated as weight (kg)/height (m2).
Waist circumference was measured in centimeters. The
average of two blood pressure (BP) measurements,
obtained at a single visit in the upright position after a
minimum of 5 minutes of rest, was used for analysis.
Metabolic syndrome (MetS) was defined, according to
Adult Treatment Panel III criteria,26 as the presence of
at least three of the following five traits: (1) abdominal
obesity, defined as a waist circumference in men
>102 cm (40 inches) and in women >88 cm (35
inches); (2) serum triglycerides (TGs) 150 mg/dL (1.7
mmol/L) or drug treatment for elevated TGs; (3) serum
HDL cholesterol (HDL-C) <40 mg/dL (1.0 mmol/L)
in men and <50 mg/dL (1.3 mmol/L) in women or
drug treatment for low HDL-C; (4) BP 130/85
mmHg or drug treatment for elevated BP; and (5) fast-
ing plasma glucose (FPG) 100 mg/dL (5.6 mmol/L)
or drug treatment for elevated blood glucose. Hyperten-
sion (HTN) was defined as BP 140/90 mmHg or
drug treatment for elevated BP. DM was defined as FPG
126 mg/dL (7.0 mmol/L) or drug treatment for ele-
vated blood glucose. The insulin resistance index was
calculated using the homeostasis model assessment of
insulin resistance (HOMA-IR): fasting glucose (mmol/
L) 3 fasting insulin (mU/L)/22.5 27.
Statistical Analysis. Baseline data were done using
descriptive statistics. Chi-square tests and Student t tests
(means) or Wilcoxon’s rank-sum tests (medians) were
used to assess the significance of differences in distribu-
tions of categorical data and continuous data, respec-
tively. To examine associations between traits and LSM
as continuous (log-transformed) dependent variable or
LSM 8.0 kPa, we performed linear or logistic regres-
sion analyses, respectively. Given that there is some dis-
cord regarding the cut-off level of LSM for presence of
advanced liver fibrosis using XL-probe, we performed
additional sensitivity analyses and tested our model
applying a 1 point lower cutoff for XL probe.15 In addi-
tion, we tested our model applying a cutoff of 9.5kPa
for advanced fibrosis, a cutoff that has been proposed in
studies including subjects with viral hepatitis.25 Interac-
tion terms between age, sex, and other covariables were
tested in linear and logistic multivariable regression
models. A combined interaction term of DM and stea-
tosis with age was constructed by dividing the total
cohort into four groups: (1) participants without DM
and steatosis; (2) participants with DM and without ste-
atosis; (3) participants with steatosis and without DM;
and (4) those with both DM and steatosis. We calcu-
lated predicted probabilities of having LSM 8.0 kPa
by using all covariables of our multivariable logistic
regression model (i.e., age, sex, spleen size, ALT, BMI,
alcohol consumption/week, smoking behavior, presence
of HBsAg and/or anti-HCV, presence of DM and/or
steatosis, and the combined interaction term). Probabil-
ities were expressed as median (IQR) percentage. Linear
regression analyses were used to assess the significance
of differences in predicted probabilities between sub-
groups of our cohort. A P value of <0.05 was consid-
ered statistically significant. Statistical analyses were
performed using SPSS software (version 21.0; SPSS,
Inc., Chicago, IL).
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Results
Study Population. Of 3,439 participants age 51 or
above who visited the research center between January
2011 and September 2013, a total of 3,342 underwent
TE (Fig. 1). Because of LSM failure, an additional 162
participants (4.8%) were excluded. LSM was reliable in
3,041 participants. Baseline characteristics of the study
population are shown in Table 1. Fifty-five percent of
3,041 participants were women, mean age of partici-
pants was 66.06 7.6 years, and mean BMI was
27.36 4.0 kg/m2. Participants were predominantly of
Caucasian ethnicity (95.1%). Median LSM was 4.7 kPa
(3.8-5.8) and 1,080 participants (35.5%) had presence
of steatosis on abdominal US. LSM 8.0 kPa, suggest-
ing presence of clinically relevant fibrosis, was detected
in 169 participants (5.6%). Twenty-two participants
had positive viral serology (7 were HBsAg positive and
16 were anti-HCV positive; 1 participant was both
HBsAg and anti-HCV positive); only 1 of these partici-
pants had ALT of 70U/L, which is 13 the ULN. Nor-
mal liver enzymes were present in 2,216 (76.0%) of all
participants. Of these 2,216 participants, 81 (3.7%) had
LSM 8.0 kPa.
Factors Associated With Liver Stiffness. Distri-
bution of LSM values in our cohort of 3,041 partici-
pants is illustrated in Fig. 2. Results of linear univariable
analyses are illustrated in Supporting Table 1. In linear
multivariable regression analysis, log-transformed LSM
was associated with higher age, male sex, presence of
DM, larger spleen size, higher ALT, presence of positive
viral serology for hepatitis B and/or C, and presence of
steatosis (Table 2). Greater HOMA-IR, indicative of
more insulin resistance, was associated with higher LSM
when we replaced presence of DM with HOMA-IR in
the model (b5 0.003; 95% confidence interval [CI]:
0.001-0.004; P< 0.001). Replacing BMI with waist cir-
cumference in the model did not alter the association
with LSM (b520.001; 95% CI: 20.001 to <0.001;
P5 0.08). No interaction between age, sex, and other
covariables was observed for the association with LSM.
Using linear regression analysis in 1,565 participants
without apparent liver disease, excluding participants
with positive HBsAg, anti-HCV, steatosis, excessive
alcohol intake, and ALT above the ULN, only higher
age (b5 0.029 per 10 years; 95% CI: 0.020-0.037;
P< 0.001) and male sex (b5 0.066; 95% CI: 0.049-
0.082; P< 0.001) remained associated with log LSM.
In these participants, the 5th and 95th percentile values
of LSM were 2.8 and 7.3 kPa, respectively. Age
(b5 0.021 per 10 years; 95% CI: 0.013-0.030;
P< 0.001) and male sex (b5 0.067; 95% CI: 0.051-
0.082; P< 0.001) remained associated with higher log
LSM after excluding an additional 51 cases with LSM
8.0 kPa.
Factors Associated With and Predicted Probabil-
ity of Clinically Relevant Fibrosis. Of 3,041 partici-
pants, 169 (5.6%) had LSM 8.0 kPa, suggesting
clinically relevant fibrosis, and 19 (0.6%) had LSM
>13.0 kPa, suggesting presence of advanced fibrosis or
cirrhosis. General characteristics of participants accord-
ing to an LSM cutoff of 8.0 kPa are shown in Table 1.
One participant with LSM 8.0 kPa had positive serum
anti-HCV, and 3 had positive serum HBsAg. Results of
logistic univariable analyses are illustrated in Supporting
Table 2. Factors associated with LSM 8.0 kPa in mul-
tivariable logistic regression analysis are shown in Table
3. Severity of steatosis was not associated with elevated
LSM, applying different cutoffs (P5 0.31 for 8.0 kPa
and P5 0.79 for 9.5 kPa). Thirteen of nineteen
(68%) participants with LSM >13.0 kPa were female;
mean age of this group was 70.06 11.8 years and mean
BMI 28.76 6.4 kg/m2. Two of these participants drank
more than 14 alcoholic beverages per week, 11 (57.9%)
participants had steatosis on USG, and 7 (38.9%) had
DM. Splenomegaly was present in 5 of 19 participants
with LSM >13.0 kPa. None of the participants with
LSM >13.0 kPa had positive viral serology for hepatitis
B or C.
We performed several sensitivity analyses to deter-
mine the robustness of our findings. Consistency was
shown, when a 1 point lower cutoff for elevated LSM
was applied for use of the XL probe or when 9.5 kPa
was used as a cutoff for clinically relevant liver fibrosis.
When participants with ALT >23 the ULN were
excluded from the analyses, given that severe
Fig. 1. Flowchart of the study. In total, 3,041 participants had a
reliable liver stiffness measurement.
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inflammation of the liver may have influenced the PPV
of presence of liver fibrosis, the prevalence of LSM 8.0
kPa was 5.2% and the same factors, with sex instead of
spleen size, remained associated with elevated log-
transformed LSM.
We calculated predicted probabilities of having LSM
8.0 kPa, taking into account all factors associated with
LSM 8.0 kPa in our multivariable model. These pre-
dicted probabilities increased incrementally with age
(Fig. 3). The adjusted probability of having LSM 8.0
kPa was 1.4% (0.9-3.6) for participants of 50-60 years
of age, 3.4% (2.1-6.0) for those ages 60-70 years, 5.5%
(3.6-8.5) for participants ages 70-80 years, and 9.9%
(6.8-14.5) for participants >80 years.
Given that the association between age and LSM
8.0 kPa was significantly influenced by the presence of
DM and/or steatosis (P for combined interaction
term5 0.04), we also calculated predicted probabilities
of having LSM 8.0 kPa per age decade for participants
with and without DM and/or steatosis (Fig. 4). These
probabilities increased per age decade for participants
without DM or steatosis (n5 1,814; 1.1% [0.8-1.6] in
Table 1. Baseline Characteristics
Characteristic
Total <8.0 kPa 8.0 kPa P Value*
n5 3,041 n5 2,872 n5 169 (5.6%)
Age, years 66.06 7.6 65.86 7.5 68.76 8.9 <0.001
Female 55.0 56.1 37.9 <0.001
Caucasian 95.1 95.0 96.9 0.3
BMI, kg/m2 27.36 4.0 27.26 3.9 28.96 5.2 <0.001
Normal; BMI <25 28.5 28.9 22.2
Overweight; 25 BMI< 30 49.2 49.7 40.1
Obese; BMI 30 22.3 21.4 37.7
Waist circumference, cm 93.76 12.2 93.36 12.0 99.76 14.2 <0.001
Alcohol consumption, drinks/week 3.8 (0.4-8.3) 3.8 (0.4-8.3) 3.8 (0.4-8.8) 0.4
Presence of HBsAg and/or anti-HCV 0.8 0.7 2.5 0.03
Smoking 0.002
Never 35.1 35.9 22.2
Former 51.8 51.2 61.1
Current 13.1 12.9 16.7
HTN† 62.4 61.5 76.7 <0.001
DM‡ 11.1 9.8 33.7 <0.001
MetS 44.0 42.9 61.9 <0.001
Waist circumference >88 cm ($) or >102 cm (#) 44.6 43.9 56.9 0.001
TGs >150 mg/dL or drug treatment for elevated TGs 37.2 36.8 44.3 0.05
HDL-C <40 mg/dL(#) or <50 mg/dL($) or drug
treatment for low HDL-C
33.5 33.0 42.5 0.01
BP 130/85 mmHg or drug treatment for elevated BP† 77.7 77.2 86.0 0.01
FPG >100 mg/dL or drug treatment for elevated blood glucose 44.7 43.2 69.9 <0.001
US characteristics
Steatosis 35.5 34.1 59.2 <0.001
Spleen size, cm§ 9.86 1.3 9.86 1.3 10.46 1.5 <0.001
Portal vein flow velocity, cm/sk 22.06 4.7 22.06 4.7 22.26 5.4 0.6
Laboratory data
ALT, U/L 18 (14-24) 18 (14-24) 22 (16-30) <0.001
AST, U/L 24 (21-28) 24 (21-28) 27 (23-36) <0.001
Bilirubin, umol/L 8 (6-11) 8 (6-11) 9 (6-12) 0.07
ALP, U/L 67 (56-78) 67 (56-78) 70 (56-87) 0.08
GGT, U/L 24 (17-35) 24 (17-34) 38 (25-67) <0.001
HOMA-IR 2.6 (1.7-3.9) 2.5 (1.7-3.8) 3.9 (2.5-6.3) <0.001
Platelets,*109/L 263 (224-306) 263 (226-307) 242 (205-288) <0.001
TE
LSM (kPa) 4.7 (3.8-5.8) 4.6 (3.8-5.6) 9.1 (8.6-10.4) <0.001
IQR/M 0.19 (0.12-0.27) 0.19 (0.12-0.27) 0.17 (0.12-0.24) 0.02
Data are represented as mean6 standard deviation, median (25th-75th percentile), or percentage.
*Based on t test, Wilcoxon’s rank-sum test, chi-square test, or Fisher’s exact test.
†BP measurement and data on drug treatment for elevated BP were available for 2,611 participants.
‡Data on presence of DM were obtained in 3,001 participants.
§Spleen-size measurement was available for 2,587 participants.
kPortal blood flow velocity was available for 2,887 participants.
Abbreviation: IQR/M, interquartile range/median LSM.
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participants ages 50-60 years vs. 10.5% [6.6-14.6] in
participants >80 years; P5 4.0*102162). Probabilities
also increased with increasing age for participants with
steatosis, but without DM (n5 853; 5.1% [3.6-7.0] vs.
8.8% [5.0-11.0]; P5 0.001). For participants with only
DM (n5 118), probabilities did not increase with age
(P5 0.76). Participants with both DM and steatosis
had the highest probabilities of having LSM 8.0 kPa
for all age decades. For these 216 participants, the over-
all probability of LSM 8.0 kPa was 17.2% (12.5-
23.4). These probabilities did not increase with age
(14.3 [12.1-18.4] vs. 17.0 [12.3-24.1] vs. 20.1 [13.5-
23.9] vs. 16.3 [12.5-23.8], respectively, per increasing
age decade; overall P5 0.76).
We also observed a second interaction in our analyses:
The association between current or former smoking and
LSM 8.0 kPa was significantly influenced by sex (P for
interaction term5 0.024). Of 1,902 previously or cur-
rently smoking participants, males had a median pre-
dicted probability of having LSM 8.0 kPa of 6.2%
(3.6-10.2), compared to a probability of 3.7% (2.1-6.8)
in female smokers (P< 0.001). These probabilities were
2.8% (1.6-5.0) and 2.4% (1.3-3.8), respectively, for
males and females who had never smoked (P< 0.001).
Liver Stiffness in Participants With NAFLD. A
subanalysis was performed to investigate factors associ-
ated with LSM in participants with NAFLD. Of 3,041
participants, 532 participants were excluded because of
presence of secondary causes associated with steatosis
(excessive alcohol consumption [n5 449], positive anti-
HCV [n5 16], positive HBsAg [n5 7], and pharmaco-
logical agents associated with steatosis [n5 69]). Eight
hundred twenty-two (32.8%) participants had NAFLD.
Mean age of participants with NAFLD was 66.06 7.2
years, mean BMI was 29.86 4.0 kg/m2, and median
LSM was 4.9 kPa (4.0-6.1). Sixty-nine (8.4%) partici-
pants of this subgroup had LSM 8.0 kPa. In
Fig. 2. Distribution of reliable liver stiffness measurements in 3,041
participants.
Table 2. Factors Associated With (Log-Transformed) LSM in
Linear Multivariable Regression Analysis (n5 3,041)
Variable b (95% CI) P Value
Age, per 10 years 0.029 (0.022-0.036) <0.001
Sex, male 0.055 (0.042-0.067) <0.001
DM 0.041 (0.023-0.059) <0.001
Spleen size, cm 0.012 (0.007-0.016) <0.001
ALT, per 10 U/L 0.014 (0.009-0.018) <0.001
BMI, kg/m2 20.001 (20.002-0.001) 0.28
Steatosis 0.024 (0.012-0.037) <0.001
Alcohol consumption, drinks/week <0.001 (20.001-0.001) 0.50
Current or former smoking 0.002 (20.009-0.013) 0.74
HBsAg or anti-HCV positive 0.090 (0.025-0.156) 0.007
Table 3. Factors Associated With LSM 8.0 kPa (n5 169)
in Logistic Multivariable Regression Analysis
Variable OR (95% CI) P Value
Age for no DM, no steatosis,
per 10 years
2.40 (1.72-3.36) <0.001
Sex, male 1.35 (0.91-2.02) 0.14
Spleen size, cm 1.23 (1.09-1.40) 0.001
ALT, per 10 U/L 1.24 (1.12-1.38) <0.001
BMI, kg/m2 1.00 (0.95-1.06) 0.97
Alcohol consumption, drinks/week 1.00 (0.98-1.03) 0.76
Current or former smoking 1.77 (1.16-2.70) 0.008
HBsAg or anti-HCV positive 5.38 (1.60-18.0) 0.006
Interaction
For age 66.0 years*
No DM, no steatosis 1 (ref) ref
Steatosis, no DM 1.99 (1.28-3.10) 0.002
DM, no steatosis 3.22 (1.39-7.42) 0.006
DM and steatosis 5.20 (3.01-8.98) <0.001
*66.0 years was the mean age in the total population.
Abbreviation: ref, reference.
Fig. 3. Predicted probabilities (%) of having LSM 8.0 kPa
increase with age. Probabilities are adjusted for age, sex, BMI, current
or former smoking, presence of DM and/or steatosis, ALT, presence of
HBsAg and/or anti-HCV, weekly alcohol consumption, spleen size, and
the interaction between age and presence of DM and/or steatosis.
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multivariable linear regression analysis, higher age
(b5 0.027 per 10 years; 95% CI: 0.012-0.042;
P< 0.001), presence of DM (b5 0.038; 95% CI:
0.010-0.065; P5 0.007), male sex (b5 0.044; 95% CI:
0.019-0.068; P5 0.001), higher ALT (b5 0.023 per
10 U/L; 95% CI: 0.014-0.032; P< 0.001), and larger
spleen size (b5 0.014; 95% CI: 0.006-0.023;
P5 0.001) were associated with higher log LSM.
Replacing presence of DM by HOMA-IR did not alter
results. Presence of DM (OR, 2.96; 95% CI: 1.60-5.47;
P5 0.001), higher ALT (OR, 1.43 per 10 U/L; 95%
CI: 1.19-1.72; P< 0.001), and increasing weekly alco-
hol consumption (OR, 1.09; 95% CI: 1.01-1.18;
P5 0.023) were associated with having LSM 8.0 kPa
in participants with NAFLD in multivariable logistic
regression analysis.
Discussion
To date, this is the largest study to investigate factors
associated with and distribution of liver fibrosis, assessed
by TE, in a general Caucasian population of older indi-
viduals. In this cross-sectional study, the prevalence of
LSM 8.0 kPa, suggestive of clinically relevant liver
fibrosis, was 5.6%. Higher age, presence of DM and/or
steatosis, higher ALT, larger spleen size, current or for-
mer smoking, and positive viral serology for hepatitis B
and/or C were independently associated with LSM
8.0 kPa.
Only few community-based studies have assessed liver
fibrosis in adults by means of TE. In a study by Roulot
et al., in which reliable LSM was obtained in 1,190 sub-
jects older than 45 years attending a free medical
checkup, prevalence of LSM 8.0 kPa was 7.5% and
risk factors of LSM 8.0 kPa were rather consistent
with our findings and included age, elevated liver
enzymes, and factors associated with MetS.21 We were
able to include ultrasonographic findings in our analyses
and found that both steatosis and spleen size were signif-
icantly associated with greater liver stiffness. Although
the prevalence of LSM 8.0 kPa in our cohorts is nearly
comparable, our study population may have included a
less-selected population, but had a higher mean age,
greater prevalence of MetS, and included more women
than the population described by Roulot et al. A cross-
sectional, community-based study by Wong et al.
assessed the prevalence of NAFLD and LSM 9.6 kPa
in Hong Kong Chinese subjects by using magnetic reso-
nance imaging and TE.20 LSM 9.6 kPa was present in
2.0% of the total cohort of 759 subjects without a hepa-
titis B or C infection and in 3.7% of subjects with
NAFLD. These percentages were comparable with our
results (data not shown), even though the prevalence of
steatosis and MetS and the mean age of our cohort were
higher.
In the present study, higher age was associated with
continuous LSM or elevated LSM in both linear and
logistic regression analysis, respectively. An association
of age with LSM has been corroborated in some previ-
ous studies, but not in others.21,28-32 Indeed, incidence
of liver diseases increases with advancing age, which
may, in part, explain a higher prevalence of LSM 8.0
kPa at higher age.33 However, we demonstrated that
higher age remained associated with higher LSM after
exclusion of subjects with positive viral serology for hep-
atitis B and/or C, steatosis, ALT above the ULN, and
LSM 8.0 kPa. Elastic properties of the normal liver
may change as a result of aging for several reasons. First,
age-related changes in histological architecture of the
Fig. 4. Predicted proba-
bilities (%) of having LSM
8.0 kPa per age decade
for participants with and
without DM and/or steato-
sis. Probabilities are
adjusted for age, sex, BMI,
current or former smoking,
presence of DM and/or ste-
atosis, ALT, presence of
HBsAg and/or anti-HCV,
weekly alcohol consumption,
spleen size, and the interac-
tion between age and pres-
ence of DM and/or
steatosis.
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liver may cause increased liver stiffness. With aging,
there is a decline in hepatic blood flow, hepatic volume,
and number and volume of individual hepatocytes.34,35
Hepatocytes in aged livers show increased polyploidy.36
Second, livers of older individuals may be stiffer as a
result of accumulation of collagen. It is hypothesized
that older individuals have reduced collagenolytic activ-
ity.37 In addition, cellular senescence, caused by telo-
mere dysfunction, and increased mitochondrial damage
and oxidative stress, may increase susceptibility of the
older liver to liver damage and may reduce the capacity
of the liver to regenerate.33
A compelling observation in our study was that the
association of age with LSM 8.0 kPa was positively
influenced by presence of steatosis and/or DM. Pre-
dicted probabilities of LSM 8.0 kPa increased with
age for participants without DM. For participants with
DM, on the other hand, the probability of having clini-
cally relevant fibrosis was already as high as 8.2%-
14.0% for participants ages 50-60 years, depending on
the concurrent presence of steatosis, and these probabil-
ities did not increase with age. These findings underline
the significant role of these—potentially modifiable—
risk factors in liver fibrosis and stress the importance of
early targeting insulin resistance and/or DM. We
observed that the presence of steatosis and/or DM did
not influence the probability of LSM 8.0 kPa in octo-
and nonagenarians, which can be the result of a survival
effect, but it may also suggest that both steatosis and
insulin resistance or DM play a less important role in
liver fibrosis at very old age. However, this remains spec-
ulative given that some selection bias may exist. In addi-
tion, this study was cross-sectional by design, and we
were therefore unable to determine the role of duration
of presence of DM or steatosis on probability of high
LSM in the very old.
Furthermore, a strong association between increased
liver stiffness and presence of DM and/or greater insulin
resistance was not only observed in the study population
as a whole, but also in a subgroup of subjects with ultra-
sonographically defined NAFLD. Prevalence of LSM
8.0 kPa in participants with NAFLD was as high as
8.4%. These findings suggest that NAFLD may be an
important determinant of clinically relevant fibrosis in a
population that has a very low prevalence of viral hepati-
tis. Given that NAFLD will become more prevalent
considering population aging and the current increasing
prevalence of DM and obesity, and because the presence
of NASH is associated with an increased overall, cardio-
vascular, and liver-related mortality, NAFLD will
become a more urgent public health issue in the next
few decades.38-41
In contrary to the observations by Roulot et al, we
found that previous or current smoking was significantly
associated with elevated liver stiffness.21 Smoking may
cause liver injury through various mechanisms, includ-
ing (in)direct toxic effects, immunological effects
through proinflammatory cytokine release, and onco-
genic effects through free radical damage.42 The harmful
effects of smoking on the liver have been investigated in
some experimental studies with rats and in smaller clini-
cal studies including patients with various liver diseases;
however, epidemiological evidence of an independent
association is limited.43-50 Although a synergism
between alcohol consumption and smoking is well
known, smoking was shown to increase the risk of LC
independent of alcohol consumption in a previous
population-based cohort study, consistent with our
study.45
The strengths of this study encompass the large num-
ber of participants that were included and extensive data
that were available for characterization of metabolic and
environmental traits. In addition, abdominal US was
performed in all participants. Our study also has some
limitations. For diagnosing liver fibrosis, biopsy remains
the gold standard. However, performing a biopsy in all
participants of this population-based cohort would have
been unethical. Therefore, we used TE to obtain LSM
for all participants. Although limited research is avail-
able addressing the PPV to rule in advanced fibrosis and
cirrhosis in subjects of the general population, TE is
considered to be a reproducible, effective noninvasive
alternative to assess liver fibrosis in patients with
CLDs.25,51 In addition, TE has also been shown to be
able to predict portal hypertension–related complica-
tions, decompensation, and survival in patients with
CLD.52,53 There is some debate regarding which criteria
to apply to determine reliability of TE. Applying the
other reliability criteria—success rate 60%, 10 valid
measurements, and IQR/median LSM 0.3—to our
cohort resulted in comparable results. Unfortunately, we
did not have access to histology to corroborate our
results. However, we expect the cutoff of 8.0 kPa for
clinically relevant fibrosis to be feasible, given that Rou-
lot et al. could determine a cause of liver disease in all
subjects with LSM 8.0 kPa in whom a biopsy was per-
formed.21 XL-probe may have a lower cut-off value for
advanced liver fibrosis, and different cutoffs have been
applied for advanced fibrosis in patients with CLDs
depending on etiology.15,25 Consistency of results was
found when different cutoffs were used in our study.
Steatosis was diagnosed by means of USG, which may
identify a degree of steatosis greater than 30%. Never-
theless, abdominal USG has an acceptable sensitivity of
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80%-100% for detecting steatosis, and its accuracy for
diagnosis of steatosis meets other imaging modalities.54-
56 Finally, there are controversial data about the influ-
ence of liver steatosis on LSM values in chronic hepatitis
C patients.57-60 In patients with NAFLD, most studies
have shown no, or an inverse, relationship between
degree of steatosis and LSM.16,19,61 Petta et al. demon-
strated an association between severity of steatosis and
LSM in NAFLD patients without significant fibrosis at
biopsy. In this study, a cutoff of 7.9 kPa—similar to the
cutoff used in the present study—was identified as the
best LSM cutoff for discriminating significant fibrosis in
presence of severe steatosis (66%) or severe bright liver
echo pattern.62 We demonstrated no association
between severity of steatosis and elevated liver stiffness
in participants with steatosis. However, we cannot com-
pletely rule out the possibility that steatosis in itself may
have affected LSM, independent of fibrosis stage, owing
to the lack of biopsies in this general population.
In summary, prevalence of LSM higher than 8.0 kPa,
suggestive of clinically relevant liver fibrosis, was 5.6%
in this older adult population-based cohort. Factors
associated with clinically relevant fibrosis were higher
age, presence of DM and/or steatosis, higher ALT,
greater spleen size, current or former smoking, and posi-
tive viral serology for hepatitis B and/or C. Presence of
DM, especially in concurrent presence of steatosis,
resulted in increased probabilities of having clinically
relevant fibrosis. In the context of an aging population
and increasing prevalence of obesity, DM, and NAFLD,
this study illustrates that liver fibrosis and its complica-
tions may become a more prominent public health issue
in the near future.
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